Medtronic plc. (MDT) is listed on NYSE in the Healthcare sector Β· Medical Devices industry. The current price is 92.58, up 0.43% from the previous close. Market cap is approximately $117.8B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
Medtronic plc. trades at a P/E of 24.35x, within the typical range for mature companies. Whether the multiple sits above or below the sector median is the cleaner relative-value read.
MDT's ROE of 9.84% is average. In this band, consistency and stability matter more than the absolute number.
MDT's D/E at 58.21 is on the high side. Credit rating, debt maturity ladder, and refinancing risk all become first-order considerations.
Revenue growth of 9.90% is in the single digits β a normal pace for mature businesses. Margin expansion and capital efficiency become the main EPS drivers.
Medtronic plc.'s 3.16% yield is standard. If the company is also buying back stock, evaluate on total shareholder return (dividends + buybacks) rather than yield alone.
Clinical trial outcomes, FDA decisions, and drug-pricing policy drive most of the short-term volatility.
Medtronic plc. trades near the midpoint (42%) of its 52-week range (73.31β106.33). With the price anchored to neither extreme, valuation and earnings tend to be more informative than price direction here.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The day's high-to-low spread reached 3.03%, with a 0.43% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Medtronic plc. (MDT) is listed on NYSE, with recent volume of 2,800,879 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.